Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP187-GC versus Tecfidera single-dose pharmacokinetic crossover study in healthy volunteers
NL-OMON42906Phase 1Active, not recruiting
- Sponsor
- Forward Pharma
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FP187-V2B and dimethyl fumarate in multiple sclerosis (MS) (4 arms), sponsored by Forward Pharma. Primary endpoints: MMF plasma AUC0-inf, MMF plasma AUC0-t and 8 more. Started May 2016; status: active, not recruiting.
02
Drugs
FP187-V2Bdimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON42906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42906.